Fig. 1
From: SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets
Development and validation of the 25-gene SARS-CoV-2 signature. a 25 gene SARS-CoV-2 signature using cell lines A549 overexpressed with ACE2 and Calu-3 infected with SARS-CoV-2 (Multiplicity of infection [MOI] 2) compared to mock-treated. b Internal and external validation of SARS-CoV-2 infection activity by using the signature in series 2, 15, bronchoalveolar lavage fluid (BALF) cells (n = 7) and peripheral blood mononuclear cells (PBMC) (n = 6) samples. Series 2 consisted of A549 cells infected with mock or SARS-CoV-2 (MOI 0.2), whereas series 15 consisted of postmortem COVID-19 patients and healthy lung biopsy samples. BALF cells and PBMC were collected from healthy and SARS-CoV-2 infected patients